*Division of Cardiovascular Sciences, Centre for Applied Medical Research, University of Navarra, 31008 Pamplona, Spain.
†Center for Heart Failure Research, Cardiovascular Research Institute Maastricht, Maastricht University, 6229 ER Maastricht, The Netherlands.
Clin Sci (Lond). 2014 Apr;126(7):497-506. doi: 10.1042/CS20130538.
miRNAs (microRNAs) have been shown to play a role in myocardial fibrosis. The present study was designed to analyse whether alterations in miRNA expression contribute to the progression of myocardial fibrosis in AS (aortic valve stenosis) patients through up-regulation of the pro-fibrotic factor TGF-β1 (transforming growth factor-β type 1). Endomyocardial biopsies were obtained from 28 patients with severe AS, and from the necropsies of 10 control subjects. AS patients presented increased myocardial CVF (collagen volume fraction) and TGF-β1 compared with the controls, these parameters being correlated in all patients. Patients were divided into two groups by cluster analysis according to their CVF: SF (severe fibrosis; CVF >15%; n=15) and non-SF (CVF ≤15%; n=13). TGF-β1 was increased in patients with SF compared with those with non-SF. To analyse the involvement of miRNAs in SF, the miRNA expression profile of 10 patients (four with non-SF and six with SF) was analysed showing that 99 miRNAs were down-regulated and 19 up-regulated in the SF patients compared with the non-SF patients. Those miRNAs potentially targeting TGF-β1 were validated by real-time RT (reverse transcription)-PCR in the whole test population, corroborating that miR-122 and miR-18b were down-regulated in patients with SF compared with those with non-SF and the control subjects. Additionally, miR-122 was inversely correlated with the CVF, TGF-β1 and the TGF-β1-regulated PCPE-1 (procollagen C-terminal proteinase enhancer-1) in all patients. Experiments in human fibroblasts demonstrated that miR-122 targets and inhibits TGF-β1. In conclusion, for the first time we show that myocardial down-regulation of miR-122 might be involved in myocardial fibrosis in AS patients, probably through TGF-β1 up-regulation.
miRNAs(microRNAs)已被证明在心肌纤维化中发挥作用。本研究旨在分析 miRNA 表达的改变是否通过上调促纤维化因子 TGF-β1(转化生长因子-β 1 型)导致 AS(主动脉瓣狭窄)患者心肌纤维化的进展。从 28 例严重 AS 患者和 10 例对照患者的心肌活检中获得组织。与对照组相比,AS 患者的心肌 CVF(胶原体积分数)和 TGF-β1 增加,所有患者的这些参数均相关。根据 CVF 将患者分为两组进行聚类分析:SF(严重纤维化;CVF>15%;n=15)和非 SF(CVF≤15%;n=13)。与非 SF 患者相比,SF 患者的 TGF-β1 增加。为了分析 SF 中 miRNA 的参与情况,分析了 10 例患者(4 例非 SF 和 6 例 SF)的 miRNA 表达谱,结果显示 SF 患者中有 99 个 miRNA 下调,19 个 miRNA 上调与非 SF 患者相比。通过实时 RT-PCR(逆转录)在整个测试人群中验证了这些潜在靶向 TGF-β1 的 miRNA,证实与非 SF 和对照受试者相比,SF 患者的 miR-122 和 miR-18b 下调。此外,miR-122 与 CVF、TGF-β1 和 TGF-β1 调节的 PCPE-1(原胶原 C 端蛋白水解酶增强子-1)在所有患者中呈负相关。人成纤维细胞实验表明,miR-122 靶向并抑制 TGF-β1。总之,我们首次表明,miR-122 在 AS 患者心肌中的下调可能与心肌纤维化有关,可能是通过 TGF-β1 的上调。